

# Suzanne Kamel-Reid

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4495561/publications.pdf>

Version: 2024-02-01

223  
papers

12,991  
citations

30070

54  
h-index

25787

108  
g-index

226  
all docs

226  
docs citations

226  
times ranked

17000  
citing authors

#	ARTICLE	IF	CITATIONS
1	Erlotinib in Lung Cancer – Molecular and Clinical Predictors of Outcome. <i>New England Journal of Medicine</i> , 2005, 353, 133-144.	27.0	1,787
2	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , 2006, 108, 28-37.	1.4	1,117
3	Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. <i>Journal of Clinical Oncology</i> , 2008, 26, 4268-4275.	1.6	674
4	Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 341-365.	2.8	524
5	Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. <i>Blood</i> , 2008, 112, 3330-3338.	1.4	350
6	Phase II Study of Temozolomide in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 3278-3285.	1.6	321
7	Fusion of retinoic acid receptor $\alpha$ to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. <i>Nature Genetics</i> , 1997, 17, 109-113.	21.4	276
8	mRNA transcript quantification in archival samples using multiplexed, color-coded probes. <i>BMC Biotechnology</i> , 2011, 11, 46.	3.3	234
9	Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. <i>Human Molecular Genetics</i> , 2009, 18, 4818-4829.	2.9	223
10	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016, 8, 109.	8.2	211
11	A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 8295-8301.	7.0	183
12	Cancer Genomics: Technology, Discovery, and Translation. <i>Journal of Clinical Oncology</i> , 2012, 30, 647-660.	1.6	173
13	A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 353-361.	2.3	172
14	Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2009, 15, 4750-4758.	7.0	170
15	Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2017, 111, 23-29.	2.0	160
16	A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2012, 120, 3898-3905.	1.4	154
17	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. <i>Cancer</i> , 2010, 116, 5599-5607.	4.1	143
18	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. <i>Blood</i> , 2010, 116, e111-e117.	1.4	141

#	ARTICLE	IF	CITATIONS
19	Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. <i>British Journal of Haematology</i> , 2009, 146, 76-85.	2.5	137
20	Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. <i>Haematologica</i> , 2009, 94, 135-139.	3.5	137
21	Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma. <i>Molecular Cancer</i> , 2010, 9, 238.	19.2	121
22	Uncommon EGFR mutations in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 109, 137-144.	2.0	120
23	A gene signature in histologically normal surgical margins is predictive of oral carcinoma recurrence. <i>BMC Cancer</i> , 2011, 11, 437.	2.6	117
24	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e173776.	7.1	116
25	Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. <i>Nature Communications</i> , 2017, 8, 15086.	12.8	107
26	Claudin 1 overexpression increases invasion and is associated with aggressive histological features in oral squamous cell carcinoma. <i>Cancer</i> , 2008, 113, 3169-3180.	4.1	105
27	Detection of occult low-grade B-cell non-hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. <i>Hepatology</i> , 1999, 29, 543-547.	7.3	99
28	Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3396-3401.	1.6	99
29	Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 115-129.	3.0	96
30	Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib. <i>Journal of Clinical Oncology</i> , 2007, 25, 2184-2190.	1.6	92
31	A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. <i>European Journal of Cancer</i> , 2005, 41, 523-530.	2.8	86
32	A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. <i>Leukemia and Lymphoma</i> , 2010, 51, 252-260.	1.3	85
33	Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 135, 184-189.	1.4	84
34	A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. <i>Genetics in Medicine</i> , 2016, 18, 128-136.	2.4	83
35	Microarray and Biochemical Analysis of Lovastatin-induced Apoptosis of Squamous Cell Carcinomas. <i>Neoplasia</i> , 2002, 4, 337-346.	5.3	82
36	Molecular cytogenetic analysis of head and neck squamous cell carcinoma: By comparative genomic hybridization, spectral karyotyping, and expression array analysis. <i>Head and Neck</i> , 2002, 24, 874-887.	2.0	81

#	ARTICLE	IF	CITATIONS
37	Phase II study of PX-866 in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1270-4.	1.2	77
38	Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial. <i>International Journal of Cancer</i> , 2013, 132, 1547-1555.	5.1	76
39	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. <i>Seminars in Oncology</i> , 2017, 44, 187-197.	2.2	76
40	Low prevalence of Human Papillomavirus in oral cavity carcinomas. <i>Head &amp; Neck Oncology</i> , 2010, 2, 6.	2.3	75
41	The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head &amp; Neck Oncology</i> , 2011, 3, 11.	2.3	75
42	Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 4-11.	2.8	72
43	Genomic testing in cancer: Patient knowledge, attitudes, and expectations. <i>Cancer</i> , 2014, 120, 3066-3073.	4.1	72
44	Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing. <i>Journal of Thoracic Oncology</i> , 2014, 9, 947-956.	1.1	72
45	High frequency of microsatellite instability in young patients with head-and-neck squamous-cell carcinoma: Lack of involvement of the mismatch repair genes MLH1 AND MSH2. <i>International Journal of Cancer</i> , 2001, 93, 353-360.	5.1	67
46	Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 764-772.	2.0	67
47	Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. <i>Cancer</i> , 2014, 120, 603-610.	4.1	64
48	Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. <i>Oncogene</i> , 1999, 18, 633-641.	5.9	59
49	Lymphatic Vessel Density, Nodal Metastases, and Prognosis in Patients With Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2005, 131, 1065.	1.2	59
50	microRNA evaluation of unknown primary lesions in the head and neck. <i>Molecular Cancer</i> , 2009, 8, 127.	19.2	59
51	Malignant Melanoma of Vulva and Vagina. <i>Journal of Lower Genital Tract Disease</i> , 2015, 19, 350-353.	1.9	58
52	Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. <i>Cancer Cytopathology</i> , 2017, 125, 615-626.	2.4	58
53	Molecular classification of oral cancer by cDNA microarrays identifies overexpressed genes correlated with nodal metastasis. <i>International Journal of Cancer</i> , 2004, 110, 857-868.	5.1	57
54	Imatinib 800Âmg daily induces deeper molecular responses than imatinib 400Âmg daily: results of <sc>SWOG</sc> S0325, an intergroup randomized <sc>PHASE II</sc> trial in newly diagnosed chronic phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2014, 164, 223-232.	2.5	56

#	ARTICLE	IF	CITATIONS
55	Inter-Laboratory Comparison of Chronic Myeloid Leukemia Minimal Residual Disease Monitoring. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 421-430.	2.8	54
56	KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies. <i>Current Oncology</i> , 2010, 17, 31-40.	2.2	54
57	Primary Low-Grade B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue Type Arising in the Urinary Bladder. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 332-336.	2.5	54
58	Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 1998, 103, 711-715.	2.5	53
59	T cell clonality assessment: past, present and future. <i>Journal of Clinical Pathology</i> , 2018, 71, 195-200.	2.0	52
60	SATB2 augments $\beta$ -catenin in head and neck squamous cell carcinoma. <i>EMBO Reports</i> , 2010, 11, 777-783.	4.5	50
61	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 1182-1191.	2.6	50
62	Molecular Genetic Analysis of Oligodendroglial Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 10-14.	1.7	49
63	Targeted use of fluorescence in situ hybridization (FISH) in cytospin preparations. <i>Cancer Cytopathology</i> , 2010, 118, 250-258.	2.4	49
64	Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss. <i>Blood</i> , 2002, 99, 2387-2396.	1.4	48
65	Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. <i>Blood Advances</i> , 2017, 1, 1729-1738.	5.2	48
66	Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis. <i>Cancer</i> , 2012, 118, 3962-3967.	4.1	47
67	The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. <i>Blood Advances</i> , 2018, 2, 2658-2671.	5.2	47
68	Detection of EGFR and KRAS mutations in fine-needle aspirates stored on Whatman FTA cards. <i>Cancer Cytopathology</i> , 2010, 118, 450-456.	2.4	46
69	Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale. <i>Clinical Chemistry</i> , 2013, 59, 938-948.	3.2	46
70	Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: drivers of oral tumorigenesis?. <i>Human Molecular Genetics</i> , 2014, 23, 2618-2628.	2.9	46
71	A Phase II Trial of Erlotinib as Maintenance Treatment After Gemcitabine Plus Platinum-based Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 255-260.	1.3	45
72	Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer. <i>Oncogene</i> , 2002, 21, 6480-6487.	5.9	44

#	ARTICLE	IF	CITATIONS
73	Equivocal p16 Immunostaining in Squamous Cell Carcinoma of the Head and Neck: Staining Patterns are Suggestive of HPV Status. <i>Head and Neck Pathology</i> , 2012, 6, 422-429.	2.6	44
74	A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. <i>Leukemia and Lymphoma</i> , 2013, 54, 760-766.	1.3	43
75	Treatment options for patients with brain metastases from EGFR / ALK -driven lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 195-202.	0.6	43
76	HPV-independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse Prognosis Compared With HPV-associated Tumors. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 391-399.	1.4	41
77	Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma. <i>Oncogene</i> , 2001, 20, 654-658.	5.9	39
78	Optimization and analysis of a quantitative real-time PCR-based technique to determine microRNA expression in formalin-fixed paraffin-embedded samples. <i>BMC Biotechnology</i> , 2010, 10, 47.	3.3	39
79	Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RAR $\alpha$ . <i>Oncogene</i> , 2004, 23, 665-678.	5.9	38
80	MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2903-2911.	1.6	37
81	Influence of FLT3 internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 6110-6117.	4.1	36
82	The use of FTA cards for preserving unfixed cytological material for high-throughput molecular analysis. <i>Cancer Cytopathology</i> , 2012, 120, 206-214.	2.4	36
83	<i>bcr/abl</i> level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. <i>American Journal of Hematology</i> , 2014, 89, 626-632.	4.1	36
84	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 84-91.	0.8	36
85	Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 261-273.	2.8	36
86	Young Patients With Oral Squamous Cell Carcinoma. <i>JAMA Otolaryngology</i> , 2006, 132, 958.	1.2	35
87	Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 842-850.	2.8	35
88	Cytoplasmic Expression of Nucleophosmin Accurately Predicts Mutation in the Nucleophosmin Gene in Patients With Acute Myeloid Leukemia and Normal Karyotype. <i>American Journal of Clinical Pathology</i> , 2010, 133, 34-40.	0.7	34
89	Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 Tj ETQq1 1 0.784314 rgBT /Overlo	1.3	33
90	BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 565-576.	2.8	32

#	ARTICLE	IF	CITATIONS
91	Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 463-471.	2.5	32
92	T-Cell Large Granular Lymphocytic Leukemia of Donor Origin Occurring After Allogeneic Bone Marrow Transplantation for B-Cell Lymphoproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2005, 123, 196-199.	0.7	31
93	Postal survey of physicians and laboratories: Practices and perceptions of molecular oncology testing. <i>BMC Health Services Research</i> , 2009, 9, 131.	2.2	30
94	Canadian guideline on genetic screening for hereditary renal cell cancers. <i>Canadian Urological Association Journal</i> , 2013, 7, 319.	0.6	30
95	Laboratory Investigation of Myeloproliferative Neoplasms (MPNs). <i>American Journal of Clinical Pathology</i> , 2016, 146, 408-422.	0.7	30
96	Comparison of Laboratory-Developed Tests and FDA-Approved Assays for <i>BRAF</i> , <i>EGFR</i> and <i>KRAS</i> Testing. <i>JAMA Oncology</i> , 2018, 4, 838.	7.1	30
97	No significance of derivative chromosome 9 deletion on the clearance kinetics of <i>BCR-ABL</i> fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. <i>Cancer</i> , 2008, 113, 772-781.	4.1	29
98	The <i>IFNG</i> ( <i>IFN-<math>\gamma</math></i> ) Genotype Predicts Cytogenetic and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2010, 16, 5339-5350.	7.0	29
99	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2014, 32, 1005-1016.	2.6	29
100	Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 759-775.	2.5	29
101	The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. <i>Lung Cancer</i> , 2018, 123, 22-29.	2.0	28
102	Co-localization of Patched and activated Sonic hedgehog to lysosomes in neurons. <i>NeuroReport</i> , 2000, 11, 581-585.	1.2	27
103	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 159-168.	2.5	27
104	Dysregulation of <i>HOX11</i> by Chromosome Translocations in T-cell Acute Lymphoblastic Leukemia: A Paradigm for Homeobox Gene Involvement in Human Cancer. <i>Leukemia and Lymphoma</i> , 1995, 16, 209-215.	1.3	26
105	Validation of <i>KRAS</i> Testing for Anti- <i>EGFR</i> Therapeutic Decisions for Patients With Metastatic Colorectal Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 26-32.	2.5	26
106	<i>BCR-ABL1</i> transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib. <i>British Journal of Haematology</i> , 2013, 160, 630-639.	2.5	26
107	Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: A pilot study. <i>Head and Neck</i> , 2004, 26, 815-822.	2.0	25
108	Design and Analytic Validation of <i>BCR-ABL1</i> Quantitative Reverse Transcription Polymerase Chain Reaction Assay for Monitoring Minimal Residual Disease. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 33-40.	2.5	24

#	ARTICLE	IF	CITATIONS
109	CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia. <i>Human Pathology</i> , 2013, 44, 2038-2046.	2.0	24
110	A Window Into Clinical Next-Generation Sequencing-Based Oncology Testing Practices. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1679-1685.	2.5	24
111	Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. <i>International Journal of Cancer</i> , 2018, 142, 57-65.	5.1	23
112	Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. <i>Haematologica</i> , 2020, 106, 56-63.	3.5	23
113	Telomerase Activity Is Upregulated in Laryngeal Squamous Cell Carcinoma. <i>Laryngoscope</i> , 2000, 110, 391-396.	2.0	22
114	Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. <i>Cancer</i> , 2008, 112, 1513-1521.	4.1	22
115	A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial. <i>Blood</i> , 2010, 116, LBA-6-LBA-6.	1.4	22
116	Telomerase Activity in Oral Squamous Cell Carcinoma. <i>JAMA Otolaryngology</i> , 1998, 124, 784.	1.2	21
117	A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 87-92.	0.4	21
118	Lung cancer in never smokers from the Princess Margaret Cancer Centre. <i>Oncotarget</i> , 2018, 9, 22559-22570.	1.8	20
119	Current Applications of Microarrays in Head and Neck Cancer Research. <i>Laryngoscope</i> , 2004, 114, 241-248.	2.0	19
120	Clinical Utility of Next-Generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience. <i>HemaSphere</i> , 2018, 2, e44.	2.7	19
121	Acute promyelocytic leukemia in patients aged 70 years and over: A single center experience of unselected patients. <i>Leukemia and Lymphoma</i> , 2007, 48, 1654-1658.	1.3	18
122	Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation. <i>Leukemia Research</i> , 2011, 35, 492-498.	0.8	18
123	Skeletal dysplasias with gracile bones: Three new cases, including two offspring of a mother with a dwarfing condition. , 1998, 76, 125-132.		17
124	Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients. <i>British Journal of Cancer</i> , 2016, 114, 616-622.	6.4	17
125	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. <i>Clinical Colorectal Cancer</i> , 2018, 17, 73-79.	2.3	17
126	Acute leukemia of donor origin arising after stem cell transplantation for acute promyelocytic leukemia. <i>Leukemia Research</i> , 2004, 28, 1107-1111.	0.8	16



#	ARTICLE	IF	CITATIONS
127	Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease. <i>Annals of Surgical Oncology</i> , 2015, 22, 1950-1958.	1.5	16
128	Additional germline findings from a tumor profiling program. <i>BMC Medical Genomics</i> , 2018, 11, 65.	1.5	16
129	Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). <i>Clinical Cancer Research</i> , 2020, 26, 2477-2486.	7.0	16
130	Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11002-11002.	1.6	16
131	A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 607-611.	2.0	15
132	A 4-gene signature from histologically normal surgical margins predicts local recurrence in patients with oral carcinoma: clinical validation. <i>Scientific Reports</i> , 2020, 10, 1713.	3.3	15
133	Expression of NPM-RAR $\pm$ fusion gene in hematopoietic cells confers sensitivity to troglitazone-induced apoptosis. <i>Oncogene</i> , 2003, 22, 6424-6435.	5.9	14
134	The aryl hydrocarbon receptor nuclear translocator (ARNT) modulates the antioxidant response in AML cells. <i>Leukemia Research</i> , 2013, 37, 1750-1756.	0.8	14
135	Clinical genomics information management software linking cancer genome sequence and clinical decisions. <i>Genomics</i> , 2013, 102, 140-147.	2.9	14
136	Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e338-e345.	2.6	14
137	Clinico-Biological Features and Prognostic Significance of PML/RAR $\pm$ Isoforms in Adult Patients with Acute Promyelocytic Leukemia Treated with All Trans Retinoic Acid (ATRA) and Chemotherapy. <i>Leukemia and Lymphoma</i> , 2004, 45, 469-480.	1.3	13
138	An emerging role for retinoid X receptor $\pm$ in malignant hematopoiesis. <i>Leukemia Research</i> , 2012, 36, 1075-1081.	0.8	13
139	Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype. <i>Human Pathology</i> , 2013, 44, 55-61.	2.0	13
140	Preclinical Assessment of Human Hematopoietic Progenitor Cell Transduction in Long-Term Marrow Cultures. <i>Human Gene Therapy</i> , 1996, 7, 2089-2100.	2.7	12
141	Lung transplantation complicated by graft-versus-host disease and confounded by incidental transfusion-associated macrochimerism. <i>Transfusion</i> , 2008, 48, 2190-2196.	1.6	12
142	Extracorporeal photopheresis in solid organ transplant-associated acute graft-versus-host disease. <i>Transfusion</i> , 2016, 56, 962-969.	1.6	12
143	Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the BRAF, EGFR, and KRAS Genes: A Study of the College of American Pathologists Molecular Oncology Committee. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 1203-1211.	2.5	12
144	Applications of Microarray Technology to Acute Myelogenous Leukemia. <i>Cancer Informatics</i> , 2009, 7, CIN.S1015.	1.9	11

#	ARTICLE	IF	CITATIONS
145	Cryptic insertion of MLL gene into 9p22 leads to MLL-MLL3 (AF9) fusion in a case of acute myelogenous leukemia. <i>Genes Chromosomes and Cancer</i> , 2004, 40, 349-354.	2.8	10
146	Molecular characterization of salivary gland malignancy using the Smgb-Tag transgenic mouse model. <i>Laboratory Investigation</i> , 2005, 85, 947-961.	3.7	10
147	Vanishing Endometrial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 271-277.	1.4	10
148	Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: Which parameter at which time point does matter?. <i>American Journal of Hematology</i> , 2010, 85, 856-862.	4.1	10
149	The Use of Targeted Therapies for Precision Medicine in Oncology. <i>Clinical Chemistry</i> , 2016, 62, 1556-1564.	3.2	10
150	Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. <i>British Journal of Haematology</i> , 2021, 193, 779-791.	2.5	10
151	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 355-357.	2.5	9
152	Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the OncoPrint Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model. <i>Journal of Clinical Oncology</i> , 2019, 37, 2620-2620.	1.6	9
153	A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 25632-25639.	1.8	9
154	T-cell large granular lymphocytic leukemia of donor origin occurring after allogeneic bone marrow transplantation for B-cell lymphoproliferative disorders. <i>American Journal of Clinical Pathology</i> , 2005, 123, 196-9.	0.7	9
155	Translation of Knowledge to Practice—Improving Awareness in NSCLC Molecular Testing. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1004-1011.	1.1	8
156	Comprehensive Evaluation of Time-to-Response Parameter as a Predictor of Long-Term Outcomes Following Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2009, 114, 1110-1110.	1.4	8
157	Endogenous Murine Leukemia Virus DNA Sequences in Murine Cell Lines: Implications for Gene Therapy Safety Testing by PCR. <i>Leukemia and Lymphoma</i> , 1996, 23, 375-381.	1.3	7
158	Exon-skipping in BCR/ABL is induced by ABL exon 2. <i>Biochemical Journal</i> , 2000, 348, 63-69.	3.7	7
159	AML refractory to primary induction with Ida-FLAG has a poor clinical outcome. <i>Leukemia Research</i> , 2018, 68, 22-28.	0.8	7
160	Improving validation methods for molecular diagnostics: application of Bland-Altman, Deming and simple linear regression analyses in assay comparison and evaluation for next-generation sequencing. <i>Journal of Clinical Pathology</i> , 2018, 71, 117-124.	2.0	7
161	Molecular Analysis of a New Variant of the CBF1 <sup>2</sup> - MYH11 Gene Fusion. <i>Leukemia and Lymphoma</i> , 2002, 43, 2021-2026.	1.3	6
162	Latency and interval therapy affect the evolution in metastatic colorectal cancer. <i>Scientific Reports</i> , 2020, 10, 581.	3.3	6

#	ARTICLE	IF	CITATIONS
163	Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 11585-11585.	1.6	6
164	Association of isocitrate dehydrogenase-1 (IDH-1) mutations with elevated oncometabolite 2-hydroxyglutarate (2HG) in advanced colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 627-627.	1.6	6
165	Knowledge of genetic testing for hereditary kidney cancer in Canada is lacking: The results of the Canadian national hereditary kidney cancer needs assessment survey. Canadian Urological Association Journal, 2014, 8, 832.	0.6	5
166	Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. Journal of Physical Education and Sports Management, 2016, 2, a001016.	1.2	5
167	Assessing the Diagnostic Yield of Targeted Next-Generation Sequencing for Melanoma and Gastrointestinal Tumors. Journal of Molecular Diagnostics, 2020, 22, 467-475.	2.8	5
168	Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial.. Journal of Clinical Oncology, 2013, 31, 6041-6041.	1.6	5
169	Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stemcell transplantation. American Journal of Hematology, 2007, 82, 758-760.	4.1	4
170	Identification of genomic predictors of non-melanoma skin cancer in solid organ transplant recipients. European Journal of Dermatology, 2009, 19, 278-280.	0.6	4
171	Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms. Blood, 2018, 132, 2201-2205.	1.4	4
172	BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. British Journal of Haematology, 2022, 196, 136-145.	2.5	4
173	Exon-skipping in BCR/ABL is induced by ABL exon 2. Biochemical Journal, 2000, 348, 63.	3.7	3
174	Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia. American Journal of Hematology, 2007, 82, 293-294.	4.1	3
175	Correlation among nuclear localization of NuMA-RAR $\alpha$ , deregulation of gene expression and leukemic phenotype of hCG-NuMA-RAR $\alpha$ transgenic mice. Leukemia Research, 2011, 35, 670-676.	0.8	3
176	The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches. Gynecologic Oncology, 2021, 162, 97-106.	1.4	3
177	Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib. Blood, 2011, 118, 606-606.	1.4	3
178	Phase II study of PX-866 in recurrent glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2053-2053.	1.6	3
179	Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 7521-7521.	1.6	3
180	Cytological preparations for molecular pathology. Cancer Cytopathology, 2013, 121, 275-275.	2.4	2

#	ARTICLE	IF	CITATIONS
181	Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) – a single center analysis. <i>Hematological Oncology</i> , 2017, 35, 810-813.	1.7	2
182	Natural Killer (NK) or NK/T Cell Lineage Large Granular Lymphocytosis Associated with Dasatinib Therapy for Philadelphia Chromosome Positive Leukemia.. <i>Blood</i> , 2008, 112, 933-933.	1.4	2
183	Genotype matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5506-5506.	1.6	2
184	Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 11060-11060.	1.6	2
185	Next-generation sequencing: Profiling gallbladder cancer (GBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 286-286.	1.6	2
186	Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1532-1532.	1.6	2
187	Disordered Expression of HIPK Family Members in MDS and AML.. <i>Blood</i> , 2004, 104, 4311-4311.	1.4	2
188	Molecular profiling of advanced biliary cancer: Lost in translation from bench to bedside.. <i>Journal of Clinical Oncology</i> , 2016, 34, 283-283.	1.6	2
189	Upfront next generation sequencing in NSCLC: A publicly funded perspective.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12062-12062.	1.6	2
190	Presence of t(1;14)(p13;p11.2) in Philadelphia chromosome-“negative” cells in a patient with chronic myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2007, 173, 83-84.	1.0	1
191	Personalized Medicine: CCO’s Vision, Accomplishments and Future Plans. <i>Healthcare Quarterly</i> , 2014, 17, 41-43.	0.7	1
192	Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response. <i>Leukemia and Lymphoma</i> , 2014, 55, 2398-2401.	1.3	1
193	Mixed fields on RhD typing as an indication of loss of heterozygosity on chromosome 1p in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2196-2199.	1.3	1
194	Real-time clinical application of next-generation sequencing (NGS): Results from a multicenter program.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11016-11016.	1.6	1
195	A targeted intervention to improve awareness to molecular testing in NSCLC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6547-6547.	1.6	1
196	Lung cancer in never-smokers from the Princess Margaret Cancer Centre.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8099-8099.	1.6	1
197	Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Centre experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 459-459.	1.6	1
198	Clinical Relevance of Vascular Endothelial Growth Factor (VEGFA) and VEGF Receptor (VEGFR2) Gene Single Nucleotide Polymorphism on the Treatment Outcomes Following Imatinib Mesylate Therapy.. <i>Blood</i> , 2008, 112, 1110-1110.	1.4	1

#	ARTICLE	IF	CITATIONS
199	Deregulation of Transcription Factors GATA-1, GATA-2 and C/EBPa in Acute Promyelocytic Leukemia.. Blood, 2008, 112, 2241-2241.	1.4	1
200	BCR/ABL Transcript At 3 Months Predicts Long-Term Outcomes Following Second Generation Tyrosine Kinase Inhibitor Therapy in the Patients with CML in Chronic Phase Who Failed Imatinib.. Blood, 2012, 120, 2777-2777.	1.4	1
201	A novel method of measuring gas phase nitric oxide concentration in cell cultures. Acta Oto-Laryngologica, 2005, 125, 1086-1090.	0.9	0
202	Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies. JCO Precision Oncology, 2018, 2, 1-20.	3.0	0
203	The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia. Leukemia Research, 2020, 88, 106285.	0.8	0
204	The value of defining molecular resistance in patients with progressive EGFR and ALK-driven lung cancer in a public system.. Journal of Clinical Oncology, 2021, 39, 3126-3126.	1.6	0
205	EAR-2: Identification of a Gene Involved in Maintenance of Clonogenicity in Haematopoiesis.. Blood, 2004, 104, 3226-3226.	1.4	0
206	Assessment of Microrna Expression in Mantle Cell Lymphoma Using High Throughput Techniques. Blood, 2008, 112, 2824-2824.	1.4	0
207	IFN- $\gamma$ (interferon-gamma) Genotype Predict Cytogenetic and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia.. Blood, 2009, 114, 2178-2178.	1.4	0
208	Low-Level FLT3-ITD Mutations Do Not Predict for Higher Relapse Rate in AML with Standard Risk Karyotype.. Blood, 2009, 114, 1591-1591.	1.4	0
209	Phase II study of PX-866 in recurrent glioblastoma.. Journal of Clinical Oncology, 2012, 30, 2051-2051.	1.6	0
210	A 7-Gene Microrna Signature Characteristic of Mantle Cell Lymphoma Reveals Focal Adhesion and Integrin Signalling, Proteasome-Mediated Degradation, and the PI3K Signalling Cascade As Important to MCL Pathogenesis. Blood, 2012, 120, 1586-1586.	1.4	0
211	Benchmarking population-based EGFR mutation testing in nonsquamous non-small cell lung cancer.. Journal of Clinical Oncology, 2013, 31, e19032-e19032.	1.6	0
212	Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Center experience.. Journal of Clinical Oncology, 2014, 32, 3572-3572.	1.6	0
213	Biomarker testing and time-to-treatment decision in patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2014, 32, 6595-6595.	1.6	0
214	Retrospective Analysis of Allogeneic Transplant Outcomes in Chronic Myeloid Leukemia Patients with Tyrosine Kinase Inhibitors Failure. Blood, 2014, 124, 4554-4554.	1.4	0
215	Somatic mutation profiling of advanced breast and ovarian cancers according to germline BRCA1/2 mutation status.. Journal of Clinical Oncology, 2015, 33, 1532-1532.	1.6	0
216	Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre.. Journal of Clinical Oncology, 2015, 33, e19006-e19006.	1.6	0

#	ARTICLE	IF	CITATIONS
217	<i>EGFR</i> mutations in NSCLC: Does ethnicity influence outcomes?. Journal of Clinical Oncology, 2015, 33, e17633-e17633.	1.6	0
218	Molecular profiling and targeted therapy in advanced endometrial cancer.. Journal of Clinical Oncology, 2015, 33, 5589-5589.	1.6	0
219	Integration of somatic molecular profiling for rare epithelial gynaecologic cancer patients.. Journal of Clinical Oncology, 2016, 34, 5509-5509.	1.6	0
220	<i>IDH</i> -1/2 mutations and associated oncometabolite 2-hydroxyglutarate (2-HG) in solid tumors.. Journal of Clinical Oncology, 2016, 34, e23210-e23210.	1.6	0
221	Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome.. Journal of Clinical Oncology, 2016, 34, 5579-5579.	1.6	0
222	Effect of brain metastases on survival and systemic treatment of EGFR/ALK-driven non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, e20527-e20527.	1.6	0
223	Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy. Blood, 2016, 128, 4263-4263.	1.4	0